heron therapeutics inc. - HRTX
HRTX
Close Chg Chg %
1.48 0.01 0.68%
Pre-Market
1.49
+0.01 (0.68%)
Volume: 665.64K
Last Updated:
Jan 14, 2026, 4:00 PM EDT
Company Overview: heron therapeutics inc. - HRTX
HRTX Key Data
| Open $1.48 | Day Range 1.46 - 1.51 |
| 52 Week Range 1.00 - 2.68 | Market Cap $273.21M |
| Shares Outstanding 183.36M | Public Float 181.64M |
| Beta 1.28 | Rev. Per Employee N/A |
| P/E Ratio N/A | EPS -$0.08 |
| Yield 0.00% | Dividend N/A |
| EX-DIVIDEND DATE | SHORT INTEREST N/A |
| AVERAGE VOLUME 1.97M |
HRTX Performance
| 1 Week | 6.47% | ||
| 1 Month | 8.03% | ||
| 3 Months | 14.73% | ||
| 1 Year | -9.20% | ||
| 5 Years | -91.61% |
HRTX Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
4
Full Ratings ➔
About heron therapeutics inc. - HRTX
Heron Therapeutics, Inc is a biotechnology company, which engages in the development of pharmaceutical products for acute care and oncology patients. Its product portfolio includes SUSTOL, CINVANTI, HTX-011 and HTX-034. The company was founded in February 1983 and is headquartered in Cary, NC.
HRTX At a Glance
Heron Therapeutics, Inc.
100 Regency Forest Drive
Cary, North Carolina 27518
| Phone | 1-858-251-4400 | Revenue | 144.29M | |
| Industry | Biotechnology | Net Income | -13,580,000.00 | |
| Sector | Health Technology | 2024 Sales Growth | 13.571% | |
| Fiscal Year-end | 12 / 2025 | Employees | 122 | |
| View SEC Filings |
HRTX Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 1.617 |
| Price to Book Ratio | N/A |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -38.925 |
| Enterprise Value to Sales | 2.438 |
| Total Debt to Enterprise Value | 0.505 |
HRTX Efficiency
| Revenue/Employee | 1,182,663.934 |
| Income Per Employee | -111,311.475 |
| Receivables Turnover | 1.829 |
| Total Asset Turnover | 0.633 |
HRTX Liquidity
| Current Ratio | 2.285 |
| Quick Ratio | 1.704 |
| Cash Ratio | 0.648 |
HRTX Profitability
| Gross Margin | 73.214 |
| Operating Margin | -7.99 |
| Pretax Margin | -9.412 |
| Net Margin | -9.412 |
| Return on Assets | -5.961 |
| Return on Equity | N/A |
| Return on Total Capital | -9.423 |
| Return on Invested Capital | -9.575 |
HRTX Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | 123.351 |
| Total Debt to Total Assets | 76.245 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | 121.243 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Heron Therapeutics Inc. - HRTX
Collapse All in section
| All values USD millions. | 2021 | 2022 | 2023 | 2024 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| 86.35M | 107.67M | 127.04M | 144.28M | |
Sales Growth
| -2.59% | +24.70% | +17.99% | +13.57% | |
Cost of Goods Sold (COGS) incl D&A
| 46.02M | 54.87M | 65.11M | 38.65M | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 3.02M | 2.89M | 2.90M | 2.49M | |
Depreciation
| 3.02M | 2.89M | 2.90M | 2.49M | |
Amortization of Intangibles
| - | - | - | - | - |
COGS Growth
| +27.17% | +19.24% | +18.64% | -40.64% | |
Gross Income
| 40.33M | 52.80M | 61.94M | 105.64M | |
Gross Income Growth
| -23.12% | +30.93% | +17.31% | +70.55% | |
Gross Profit Margin
| +46.70% | +49.04% | +48.75% | +73.21% |
| 2021 | 2022 | 2023 | 2024 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 256.55M | 222.06M | 172.55M | 117.17M | |
Research & Development
| 130.82M | 103.31M | 55.90M | 16.68M | |
Other SG&A
| 125.73M | 118.75M | 116.66M | 100.48M | |
SGA Growth
| -8.57% | -13.45% | -22.29% | -32.10% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| - | - | 1.60M | 5.40M | - |
EBIT after Unusual Expense
| (217.83M) | (174.66M) | (110.61M) | (11.53M) | |
Non Operating Income/Expense
| (445.00K) | (4.89M) | 3.92M | 3.98M | |
Non-Operating Interest Income
| 433.00K | 1.64M | 3.36M | 3.55M | |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| 2.41M | 2.47M | 3.87M | 6.03M | |
Interest Expense Growth
| +26.78% | +2.66% | +56.35% | +55.95% | |
Gross Interest Expense
| 2.41M | 2.47M | 3.87M | 6.03M | |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| (220.68M) | (182.02M) | (110.56M) | (13.58M) | |
Pretax Income Growth
| +2.90% | +17.52% | +39.26% | +87.72% | |
Pretax Margin
| -255.58% | -169.05% | -87.02% | -9.41% | |
Income Tax
| - | - | - | - | - |
Income Tax - Current - Domestic
| - | - | - | - | - |
Income Tax - Current - Foreign
| - | - | - | - | - |
Income Tax - Deferred - Domestic
| - | - | - | - | - |
Income Tax - Deferred - Foreign
| - | - | - | - | - |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| (220.68M) | (182.02M) | (110.56M) | (13.58M) | |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| (220.68M) | (182.02M) | (110.56M) | (13.58M) | |
Net Income Growth
| +2.90% | +17.52% | +39.26% | +87.72% | |
Net Margin Growth
| -255.58% | -169.05% | -87.02% | -9.41% | |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| (220.68M) | (182.02M) | (110.56M) | (13.58M) | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| (220.68M) | (182.02M) | (110.56M) | (13.58M) | |
EPS (Basic)
| -2.2411 | -1.6718 | -0.8004 | -0.0891 | |
EPS (Basic) Growth
| +10.49% | +25.40% | +52.12% | +88.87% | |
Basic Shares Outstanding
| 98.47M | 108.88M | 138.13M | 152.45M | |
EPS (Diluted)
| -2.2411 | -1.6718 | -0.8004 | -0.0891 | |
EPS (Diluted) Growth
| +10.49% | +25.40% | +52.12% | +88.87% | |
Diluted Shares Outstanding
| 98.47M | 108.88M | 138.13M | 152.45M | |
EBITDA
| (213.21M) | (166.37M) | (107.72M) | (9.04M) | |
EBITDA Growth
| +5.37% | +21.97% | +35.25% | +91.61% | |
EBITDA Margin
| -246.92% | -154.51% | -84.79% | -6.26% |
Snapshot
| Average Recommendation | BUY | Average Target Price | 4.75 | |
| Number of Ratings | 4 | Current Quarters Estimate | -0.023 | |
| FY Report Date | 12 / 2025 | Current Year's Estimate | N/A | |
| Last Quarter’s Earnings | -0.10 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | -0.10 | Next Fiscal Year Estimate | 0.122 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 4 | N/A | 4 | 3 |
| Mean Estimate | -0.02 | N/A | 0.00 | 0.12 |
| High Estimates | 0.00 | N/A | 0.05 | 0.15 |
| Low Estimate | -0.03 | N/A | -0.05 | 0.09 |
| Coefficient of Variance | -66.67 | N/A | N/A | 24.78 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 4 | 4 | 4 |
| OVERWEIGHT | 0 | 0 | 0 |
| HOLD | 0 | 0 | 0 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 0 | 0 | 0 |
| MEAN | Buy | Buy | Buy |
SEC Filings for Heron Therapeutics Inc. - HRTX
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Heron Therapeutics Inc. - HRTX
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Nov 5, 2025 | William P. Forbes EVP, Chief Development Officer | 152,027 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Nov 5, 2025 | Ira Duarte EVP, Chief Financial Officer | 152,027 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Nov 5, 2025 | Ira Duarte EVP, Chief Financial Officer | 179,786 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Nov 5, 2025 | Craig A. Collard Chief Executive Officer; Director | 452,253 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Nov 5, 2025 | Craig A. Collard Chief Executive Officer; Director | 523,124 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Nov 5, 2025 | William P. Forbes EVP, Chief Development Officer | 166,203 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Aug 13, 2025 | Rubric Capital Management LP | 29,100,728 | Open market or private purchase of non-derivative security Non-derivative transaction at $1.5 per share | 43,651,092.00 |
| Aug 13, 2025 | Rubric Capital Management LP | N/A | Open market or private purchase of non-derivative security | 0.00 |
| Aug 13, 2025 | Velan Capital Investment Management LP Director | 8,753,290 | Open market or private purchase of non-derivative security Non-derivative transaction at $1.5 per share | 13,129,935.00 |
| Feb 4, 2025 | Susan Rodriguez Director | 87,180 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 4, 2025 | Susan Rodriguez Director | 35,900 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 4, 2025 | Craig A. Johnson Director | 83,770 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 4, 2025 | Craig A. Johnson Director | 35,900 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 4, 2025 | Christian Waage Director | 84,130 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 4, 2025 | Christian Waage Director | 35,900 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 4, 2025 | Michael Kaseta Director | 55,829 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 4, 2025 | Michael Kaseta Director | 35,900 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 4, 2025 | Sharmila Dissanaike Director | 87,180 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 4, 2025 | Sharmila Dissanaike Director | 35,900 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |